Novo Nordisk reported DKK194.05B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Bausch Health Companies USD -554M 910M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 46.13B 1.38B Dec/2025
Novo Nordisk DKK 194.05B 24.15B Dec/2025
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pacira USD 693.11M 34.1M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025